دورية أكاديمية
The comparative efficacy and tolerability of CGP 56697 (artemether+lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France
| العنوان: | The comparative efficacy and tolerability of CGP 56697 (artemether+lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France |
|---|---|
| المؤلفون: | Van Agtmael, Michiel, Bouchaud, Olivier, Malvy, Denis, Delmont, Jean, Danis, Martin, Barette, Stéphane, Gras, Claude, Bernard, Jacques, Touze, Jean Etienne, Gathmann, Insa, Mull, Robert |
| المصدر: | Van Agtmael , M , Bouchaud , O , Malvy , D , Delmont , J , Danis , M , Barette , S , Gras , C , Bernard , J , Touze , J E , Gathmann , I & Mull , R 1999 , ' The comparative efficacy and tolerability of CGP 56697 (artemether+lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France ' , International Journal of Antimicrobial Agents , vol. 12 , no. 2 , pp. 159-169 . https://doi.org/10.1016/S0924-8579Test(99)00070-9 |
| سنة النشر: | 1999 |
| الوصف: | CGP 56697 (Riamet(TM)) is a new oral anti-malarial drug composed of artemether and lumefantrine (benflumetol) which combines the fast, short-acting artemether for rapid parasite clearance with the prolonged action of lumefantrine for intended radical cure. In this double-blind, comparative trial, the efficacy and tolerability of CGP 56697, given as a course of 4x4 tablets over 48 h, was compared to halofantrine, given as 3x2 tablets over 12 h with a second course 1 week later. Patients (mostly non-immune) with acute, uncomplicated Plasmodium falciparum infection were randomly assigned to either CGP 56697 (n=51) or halofantrine (n=52). CGP 56697 proved superior with respect to parasite clearance time (median 32 vs. 48 h, P<0.001) and parasite reduction at 24 h (median 99.7 vs. 89.6%, P<0.001) with a non-significant difference in resolution of fever (median 24 vs. 32 h, P=0.835). However, a 28-day cure rate of 82% was observed for CGP 56697 and 100% for halofantrine. Significant QTc prolongations (>30 ms) were seen 6-12 h after halofantrine intake but not after CGP 56697 intake. CGP 56697 is an effective, well-tolerated treatment for uncomplicated falciparum malaria but for this dosing regimen the recrudescence rate is unacceptably high (18%). For travellers contracting malaria abroad, we propose a six-dose regimen of CGP 56697 over 3 days. Copyright (C) 1999 Elsevier Science B.V. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.vumc.nl/en/publications/548c9b06-b5cd-4f3d-8d97-2dba13743dedTest |
| DOI: | 10.1016/S0924-8579(99)00070-9 |
| الإتاحة: | https://doi.org/10.1016/S0924-8579Test(99)00070-9 https://research.vumc.nl/en/publications/548c9b06-b5cd-4f3d-8d97-2dba13743dedTest http://www.scopus.com/inward/record.url?scp=0033038463&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.A28D1BC4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S0924-8579(99)00070-9 |
|---|